2seventy bio, Inc. (NASDAQ:TSVT) CFO Sells $12,830.40 in Stock

2seventy bio, Inc. (NASDAQ:TSVT) CFO Victoria Eatwell sold 2,592 shares of the stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $4.95, for a total transaction of $12,830.40. Following the completion of the sale, the chief financial officer now owns 444,387 shares of the company’s stock, valued at approximately $2,199,715.65. The trade was a 0.58 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

2seventy bio Price Performance

Shares of TSVT opened at $4.95 on Friday. The company has a market capitalization of $255.36 million, a PE ratio of -2.66 and a beta of 1.73. 2seventy bio, Inc. has a one year low of $2.29 and a one year high of $5.99. The company’s fifty day moving average price is $2.99 and its 200 day moving average price is $3.71.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of 2seventy bio in a research report on Friday, March 7th. Morgan Stanley cut their price target on shares of 2seventy bio from $6.00 to $5.00 and set an “equal weight” rating on the stock in a report on Friday, March 14th. Leerink Partners restated a “market perform” rating and set a $5.00 price target (down previously from $9.00) on shares of 2seventy bio in a report on Tuesday, March 11th. Finally, Leerink Partnrs downgraded shares of 2seventy bio from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 11th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average target price of $6.67.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Erste Asset Management GmbH bought a new position in 2seventy bio in the 3rd quarter worth $25,000. China Universal Asset Management Co. Ltd. acquired a new stake in 2seventy bio in the 4th quarter worth $32,000. BNP Paribas Financial Markets acquired a new stake in 2seventy bio in the 4th quarter worth $35,000. ProShare Advisors LLC acquired a new stake in 2seventy bio in the 4th quarter worth $48,000. Finally, Raymond James Financial Inc. acquired a new stake in 2seventy bio in the 4th quarter worth $52,000. Institutional investors own 93.90% of the company’s stock.

2seventy bio Company Profile

2seventy bio, Inc, a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. The company's products pipeline includes Abecma, a chimeric antigen receptor T-cell product candidates for the treatment of multiple myeloma.